Acinetobacter Infections

01/01/2022 - "Randomized comparative studies are needed to confirm the efficacy of LD colistin regimen on MDR Acinetobacter infection."
04/01/2018 - "A significant difference was observed in favour of IVCC when high-dose (>6 million international units) colistin was used (RR 0.80, 95% CI 0.69-0.93), in studies conducted in Asia (RR 0.82, 95% CI 0.71-0.95), in patients with bacteraemia (RR 0.75, 95% CI 0.57-0.98) and in patients with acinetobacter infections (RR 0.88, 95% CI 0.78-1.00). "
08/01/2013 - "A total of 46 patients who had been administered intravenous colistin treatment for colistin-susceptible-only Acinetobacter infections were included in the study. "
02/11/2022 - "However, the appearance of resistance to colistin also makes treatment of the Acinetobacter infections very difficult. "
06/01/2020 - "However, mortality rates are high in patients with Acinetobacter infection receiving colistin treatment. "

01/01/2018 - "Sulbactam is a plausible option for treating Acinetobacter infections because of its intrinsic antibacterial activity against the members of the Acinetobacter genus, but the mechanisms of sulbactam resistance have not been fully studied in Acinetobacter baumannii In this study, a total of 2,197 clinical A. "
01/01/2021 - "Because sulbactam is also susceptible to cleavage by numerous β-lactamases, its clinical utility for the treatment of contemporary Acinetobacter infections is quite limited. "
03/01/2002 - "Multiresistant Acinetobacter infections: a role for sulbactam combinations in overcoming an emerging worldwide problem."
03/15/2023 - "Efficacy of Cefoperazone Sulbactam in Patients with Acinetobacter Infections: A Systematic Review of the Literature."
01/01/2023 - "Sulbactam is a first-generation, narrow-spectrum β-lactamase inhibitor that also has intrinsic antibacterial activity against Acinetobacter spp. due to its ability to inhibit penicillin-binding proteins 1 and 3. The clinical utility of sulbactam for the treatment of contemporary Acinetobacter infections has been eroded over the last decades due to its susceptibility to cleavage by numerous β-lactamases present in this species. "

07/20/2022 - "calcoaceticus and identify several antibiotics that could be beneficial in treating Acinetobacter infections."
11/15/2023 - "Acinetobacter infections are resistant to most antibiotics and can be found in hospitalized patients. "
06/16/2021 - "Thus, fimsbactin-B-based antibiotic delivery can be an effective approach in combating antibiotic-resistant Acinetobacter infections."
11/01/2017 - "To overcome the limitations of existing drugs, combination theraphy that can increase the activity of antibiotics should be considered in the treatment of Acinetobacter infections. "
05/08/2017 - "Detection of antibiotic resistant Acinetobacter baumannii in various hospital environments: potential sources for transmission of Acinetobacter infections."

01/01/2022 - "The aim of this study was to provide a descriptive account of carbapenem resistance and risk factors for mortality from invasive Acinetobacter infections in the south of Sweden. "
01/09/2014 - "The aim of the present study was to evaluate the changes in the prevalence of Acinetobacter infection by restricting the consumption of carbapenems in intensive care unit patients. "
01/01/2020 - "Carbapenems are currently the preferred agents for the treatment of serious Acinetobacter infections. "
01/01/2020 - "radioresistens and its role in dissemination of carbapenem resistance genes underlines the importance of species-level identification in Acinetobacter infections."
07/01/2017 - "Mortality In Patients With Respiratory And Nonrespiratory Carbapenem Resistant-Multidrug Resistant Acinetobacter Infections."

10/01/2008 - "Further clinical trials are needed to confirm the efficacy of tigecycline in the management of MDR Acinetobacter infections."
09/01/2008 - "Data from more studies are needed before tigecycline can be recommended for the treatment of Acinetobacter infections."
01/01/2014 - "The activity of tigecycline should be evaluated, as this is commonly used as last-resort option for the treatment of multidrug-resistant Acinetobacter infections."
11/01/2008 - "Comment: tigecycline for the treatment of Acinetobacter infections: a case series."
09/01/2008 - "A retrospective review was conducted of the medical records of 29 sequential patients who received tigecycline for treatment of Acinetobacter infections. "

03/01/2002 - "Therefore, ampicillin-sulbactam is a sensible option for the treatment of life-threatening acinetobacter infections."
03/01/2002 - "Furthermore, ampicillin-sulbactam has proven clinically effective and well tolerated in the treatment of severe acinetobacter infections, including bacteremia. "
04/01/2013 - "The objective of this study was to evaluate whether the outcomes of carbapenem-resistant Acinetobacter infections treated with ampicillin/sulbactam were associated with the in vitro susceptibility profiles. "

01/01/2023 - "Despite the alarming increase in multidrug resistance, a safe and effective vaccine for Acinetobacter infections is still not available. "
01/01/2017 - "Collectively, the defined live attenuated ΔtrxA strain is a vaccine candidate against emerging MDR Acinetobacter infection."

03/15/2023 - "Efficacy of Cefoperazone Sulbactam in Patients with Acinetobacter Infections: A Systematic Review of the Literature."
10/30/2012 - "[Cefoperazone-sulbactam plus minocycline in the treatment of extensively drug resistant Acinetobacter infections]."

01/01/2017 - "Vaccination with a live attenuated Acinetobacter baumannii deficient in thioredoxin provides protection against systemic Acinetobacter infection."

04/01/2008 - "Since colistin which is one of the alternative antimicrobial treatment choices for resistant Acinetobacter infections, is not found in Turkey, sulbactam-ampicillin might be an effective and safe choice for the treatment of multi-resistant A. "

04/15/2008 - "Because therapeutic options are limited for multidrug-resistant Acinetobacter infection, the development or discovery of new therapies, well-controlled clinical trials of existing antimicrobial regimens and combinations, and greater emphasis on the prevention of health care-associated transmission of multidrug-resistant Acinetobacter infection are essential."
01/01/2022 - "With few effective antimicrobials available for treatment of this pathogen, immune-based therapy becomes an attractive strategy to combat multi-drug resistant Acinetobacter infection. "
01/01/2022 - "In fact, PAA derivatives constitute a group of FDA-approved nonsteroidal anti-inflammatory drugs that could potentially be repurposed as antivirulence therapies to target multidrug-resistant Acinetobacter infections."
07/01/2019 - "Alternative therapy for resistant Acinetobacter infection is currently the subject of intense interest and research. "
06/01/2017 - "This resistance often leads to devastatingly long delays in time to appropriate therapy and increased mortality for patients afflicted with Acinetobacter infections. "

04/01/2013 - "This study was designed to evaluate the results of the patients who developed Acinetobacter infection in the ICU after liver transplantation. "
04/01/2013 - "Acinetobacter infection in a liver transplantation intensive care unit."
04/01/2013 - "Acinetobacter infections in the ICU after liver transplantation were asociated with a high mortality presenting with thrombocytopenia."

12/01/2021 - "Incidence, outcomes, and predictors of Acinetobacter infection in Saudi Arabian critical care units."
11/01/2000 - "Acinetobacter infection in neurosurgical intensive care patients."
11/01/1994 - "All the patients were surgical intensive care unit residents and had predisposing factors for acinetobacter infection. "
02/01/2014 - "Trauma is associated with a better prognosis in intensive care patients with Acinetobacter infections."

12/01/2021 - "Adjusted (multivariable) analysis revealed the risk of clinically-manifest Acinetobacter infection to increase the longer patients were on mechanical ventilation. "
04/01/2012 - "Our data showed that Acinetobacter infection in the respiratory tract, implementation of intubation, mechanical ventilation and high APACHE II scores were the major risk factors related to mortality."
04/13/2002 - "Today Acinetobacter infections are essentially pneumonia in patients under mechanical ventilation. "

01/01/2007 - "Multivariable analysis controlling for severity of illness and underlying disease identified an independent association between patients with MDR Acinetobacter infection (n = 96) and increased hospital and intensive care unit length of stay compared with 91 patients with susceptible Acinetobacter infection (odds ratio [OR] 2.5, 95% confidence interval [CI] 1.2-5.2 and OR 2.1, 95% CI 1.0-4.3] respectively) and 89 uninfected patients (OR 2.5, 95% CI 1.2-5.4 and OR 4.2, 95% CI 1.5-11.6] respectively). "
11/01/2000 - "Acinetobacter infection was not significantly related to the length of hospital stay prior to surgery but was related significantly to the length of stay in the ICU after surgery. "
01/01/2006 - "Limited evidence shows effectiveness in patients with resistant Acinetobacter infection in an intensive care unit, and the possibility that the use of tigecycline may reduce length of hospital stay. "